TELA Bio director receives stock compensation grant

Plovanic William J. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Plovanic William J. reported acquisition or exercise transactions in this Form 4 filing.

TELA Bio, Inc. director William J. Plovanic received a grant of 20,930 shares of common stock, valued at $0.785 per share, as compensation. The shares were issued in lieu of cash under the company’s Amended and Restated Non-Employee Director Compensation Policy and are fully vested, bringing his direct holdings to 44,530 shares.

Insider Trade Summary

Grant/Award: 20,930 shares

Grant/Award 1 txn

Insider Plovanic William J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	20,930	$0.785	$16K

Holdings After Transaction: Common Stock — 44,530 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of cash compensation under the Issuer's Amended and Restated Non-Employee Director Compensation Policy. All shares are fully vested.

Key Figures

Shares granted: 20,930 shares Grant value per share: $0.785 per share Post-transaction holdings: 44,530 shares

3 metrics

Shares granted 20,930 shares Common stock issued as director compensation in lieu of cash

Grant value per share $0.785 per share Reported price for the 20,930-share common stock award

Post-transaction holdings 44,530 shares Total common shares directly owned by Plovanic after the grant

Key Terms

in lieu of cash compensation, Amended and Restated Non-Employee Director Compensation Policy, fully vested, non-derivative

4 terms

in lieu of cash compensation financial

"Represents shares of common stock issued in lieu of cash compensation"

Amended and Restated Non-Employee Director Compensation Policy financial

"under the Issuer's Amended and Restated Non-Employee Director Compensation Policy"

fully vested financial

"All shares are fully vested"

non-derivative financial

"transaction_type": "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TELA (TELA) director William J. Plovanic report on this Form 4?

William J. Plovanic reported receiving 20,930 shares of TELA Bio common stock as a grant. The shares were issued in lieu of cash compensation for director service and are fully vested, increasing his direct holdings to 44,530 shares.

How many TELA (TELA) shares did Plovanic hold after the reported transaction?

After the transaction, Plovanic directly held 44,530 shares of TELA Bio common stock. This total includes the newly granted 20,930 fully vested shares issued as stock compensation instead of cash under the company’s non-employee director compensation policy.

Was the TELA (TELA) Form 4 transaction an open-market purchase or a compensation award?

The Form 4 reports a compensation award, not an open-market purchase. Plovanic received 20,930 shares of common stock issued in lieu of cash compensation under TELA Bio’s Amended and Restated Non-Employee Director Compensation Policy.

What was the reported value per share of the TELA (TELA) stock grant?

The stock grant was reported at $0.785 per share. Applying this per-share value to the 20,930 granted shares provides the basis for valuing the director’s compensation that was paid in stock rather than in cash for his board service.

Are the TELA (TELA) shares granted to Plovanic subject to vesting conditions?

The reported 20,930 shares are described as fully vested. According to the footnote, these common shares were issued in lieu of cash compensation under the non-employee director compensation policy and are not subject to further vesting restrictions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plovanic William J.

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		20,930(1)	A	$0.785	44,530	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of cash compensation under the Issuer's Amended and Restated Non-Employee Director Compensation Policy. All shares are fully vested.

	/s/ Megan Smeykal, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)